The approval of selpercatinib marks the first targeted therapy for pediatric patients with RET gene alterations in solid and thyroid tumors.
Selpercatinib has received accelerated approval from the FDA for the treatment of pediatric patients aged 2 years and older with advanced or metastatic medullary thyroid cancer with a RET mutation, advanced or metastatic thyroid cancer with a RET fusion, and locally advanced or metastatic solid tumors with a RET gene fusion.1
This marks the first approved targeted therapy for pediatric patients with RET gene alterations.
The drug’s efficacy was verified in the phase 1/2 LIBRETTO-121 study. In the trial, patients received 92 mg/m2 of selpercatinib orally twice daily until disease progression, unacceptable toxicity, or other reason for treatment discontinuation. Patients aged 2 to 20 with RET-activated locally advanced or metastatic solid tumors that were nonresponsive to available therapies or did not have standard systemic treatments available were evaluated.
The confirmed overall response rate (ORR) was 48% (95% CI, 28%-69%) as confirmed by blinded independence central review. The median duration of response (DOR) was not reached (95% CI, not evaluable [NE]-NE), and 92% of responders were still in response at 12 months.
In patients with RET-mutant medullary thyroid cancer (n = 14), the ORR was 43% (95% CI, 18%-71%), and among those with RET fusion-positive thyroid cancer, the ORR was 60% (95% CI, 26%-88%).
Thyroid cancer of a woman, medically 3D illustration, front view: © Axel Kock - stock.adobe.com
Regarding safety, the most common adverse events (AEs; ≥25%) were musculoskeletal pain, diarrhea, headache, vomiting, coronavirus infection, abdominal pain, fatigue, pyrexia, and hemorrhage. Grade 3 or 4 laboratory abnormalities observed in at least 5% of patients were decreased calcium, decreased hemoglobin, and decreased neutrophils.
The primary end points of phase 2 of LIBRETTO-121 are ORR and ORR based on response assessment in neuro-oncology.2 Secondary end points included pharmacokinetics, investigator-assessed ORR, DOR, progression-free survival, overall survival, clinical benefit rate, and incidence of AEs.
Patients with a Karnofsky or Lansky score of at least 50, adequate laboratory levels, and evidence of an activating RET gene alteration were eligible for enrollment in the study. Those with uncontrolled cardiovascular disease, uncontrolled systemic infection, uncontrolled hyperthyroidism or hypothyroidism, or active malabsorption syndrome were not eligible for participation.
Anticipating Novel Options for the RAI-Refractory DTC Armamentarium
May 15th 2023In season 4, episode 6 of Targeted Talks, Warren Swegal, MD, takes a multidisciplinary look at the RAI-refractory differentiated thyroid cancer treatment landscape, including the research behind 2 promising systemic therapy options.
Listen
Wirth Explores Challenges of Therapy Selection for RAI-Refractory Differentiated Thyroid Cancer
June 28th 2024During a Case-Based Roundtable® event, Lori J. Wirth, MD, discussed with participants how they approach use of lenvatinib and other therapy for patients with radioactive iodine–refractory differentiated thyroid cancer.
Read More
FDA Grants RMAT Designation to TSC-100 and TSC-101 for Hematologic Malignancies
June 1st 2024The FDA granted a regenerative medicine advanced therapy designation to TSC-100 and TSC-101 for hematologic malignancies based on encouraging ALLOHA trial data, offering expedited development and review.
Read More